Published in Gene Therapy Weekly, February 21st, 2002
Mologen-owned MIDGE technology provides Schering AG with a safe and efficient DNA vector system. MIDGE may transfer into the cells of patients to deliver gene information, e.g., for the treatment of cancers or the regeneration of tissues. A third party in the project is SynerGene Therapeutics, Inc., located in Washington, DC, which also develops solutions for targeted delivery of therapeutics. By combining both...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.